https://ipharmag.com/article/gsk-q2-results-cost-cutting-oncology-growth iPharmag en 2026-07-29T17:30:10+00:00 GSK Posts 5% Sales Growth and Targets £1.9 Billion in Cost Cuts to Fund Its Pipeline https://ipharmag.com/article/glp-1-manufacturing-skills-shortage-biopharma iPharmag en 2026-07-29T17:30:10+00:00 The Hidden Bottleneck Behind the Weight-Loss Boom: Not Enough People Who Can Make the Drugs https://ipharmag.com/article/altimmune-pemvidutide-glp-1-alcohol-use-disorder iPharmag en 2026-07-29T17:30:10+00:00 A GLP-1 Drug Cut Heavy Drinking in a Trial for Alcohol Use Disorder https://ipharmag.com/article/sage-causaly-ai-drug-discovery-journal-licensing iPharmag en 2026-07-29T17:30:10+00:00 Publisher Sage Licenses 400 Journals to Causaly's AI Drug-Discovery Platform https://ipharmag.com/article/two-drug-vs-three-drug-hiv-treatment-immune-recovery iPharmag en 2026-07-29T17:30:10+00:00 For Untreated HIV, a Two-Drug Regimen Matched Three Drugs on Immune Recovery https://ipharmag.com/article/johnson-johnson-5-5-billion-talc-settlement iPharmag en 2026-07-28T20:55:37+00:00 Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End a Decade of Lawsuits https://ipharmag.com/article/otsuka-simtriyo-centanafadine-adhd-fda-approval iPharmag en 2026-07-28T20:55:37+00:00 FDA Approves Simtriyo, a First-in-Class Non-Stimulant ADHD Drug https://ipharmag.com/article/freenome-simplescreen-colon-cancer-blood-test-fda iPharmag en 2026-07-28T20:55:37+00:00 FDA Approves a New Blood Test for Colorectal Cancer Screening https://ipharmag.com/article/gipr-brain-receptor-weight-loss-paradox-cambridge iPharmag en 2026-07-28T20:55:37+00:00 Solved: Why Both Blocking and Boosting One Brain Receptor Helps Weight Loss